RCT was conducted to evaluate efficacy and safety of drug simvastatin compared to placebo in reducing mortality and morbidity in patients with coronary heart disease. Subjects were followed up on average 5.4 years. Over the duration of the follow-up, 63 subjects died due to heart attack among 2,223 subjects in the placebo group compared to 30 deaths among 2,221 patients in the simvastatin drug group

Question #3. What is the Absolute Risk Reduction per 1,000 patients per 1 year (i.e. per 1,000 person*years)

Provide your answer with 2 digits after decimal point (two decimal places)!